Our mRNA Vaccine Future - The Cure-All For Whatever Ails Us

During the pandemic, mRNA vaccine technology took centre stage in the battle against the SARS-CoV-2 vaccine, the first time that the technology was used in anything but relatively small laboratory trials.  Despite the growing evidence that these vaccines were responsible for a significant number and variety of adverse side effects and that they weren't terribly effective at preventing the spread of COVID-19, this would appear to have opened the door to even wider use of mRNA vaccines.

 

Here is a screen capture from Moderna's clinical trials website recalling that Moderna was the purveyor of the Spikevax COVID mRNA vaccine:

 

This Phase 1/2 clinical trial will evaluate the safety and efficacy of the company's mRNA-4359 vaccine which is being designed to slow or prevent the growth of solid tumour cancers in adults.  Apparently, preclinical testing in both cell and animal models of cancer provided initial evidence that the mRNA-4359 vaccine had an impact on the immune system which provided the rationale necessary for it to be offered in Phase 1/2 clinical trials.

  

Participants in the study must:

 

1.) Be 18 years of age or older

 

2.) Have confirmed locally advanced or metastatic cancer - Includes: cutaneous melanoma, NSCLC, non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, MSS CRC, basal cell carcinoma, or triple-negative breast cancer - Also includes: confirmed locally advanced or metastatic melanoma or NSCLC who have received previous checkpoint inhibitor therapy

 

3.) Have experienced disease progression after receiving standard-of-care therapies or be intolerant to standard-of-care treatment

 

Participants that have active central nervous system tumours or metastases are excluded from the study.

 

Participants are expected to attend 17 visits to the trial site over three years with a treatment period of approximately 6 months followed by a 90 day safety followup and a two year followup period.  The vaccine will be administered as an intramuscular injection and pembrolizumab will be administered intravenously.  I found it interesting that this Phase 1/2 trial is taking three years to complete (not including a further Phase 3 trial) whereas the trials prior to the rollout of the COVID-19 mRNA vaccines took place in less than a year.

 

Participants will be assigned to one of three treatment Arms as follows:

 

1.) Arm 1a

This group will aim to treat adults who have locally advanced or metastatic cancer (cutaneous melanoma, non-small-cell lung carcinoma [NSCLC], non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer [MSS CRC], basal cell carcinoma, or triple negative breast cancer) who have previously received treatment for their cancer.

Participants assigned to Arm 1a will receive the investigational treatment.

The goal of Arm 1a is to determine a safe dose of the investigational treatment.

2.) Arm 1b

This group will include adults who have locally advanced or metastatic melanoma or NSCLC who previously received immunotherapy (called checkpoint inhibitor therapy) for their cancer.

Participants assigned to Arm 1b will receive the investigational treatment in combination with pembrolizumab.

The goal of Arm 1b is to determine a safe dose of the investigational treatment in combination with pembrolizumab.

3.) Pharmacodynamic Arm

In addition to the goals of Arm 1b, researchers will also be evaluating how the investigational treatment and pembrolizumab affect the immune system and the cancer in a group called the Pharmacodynamic (PD) Arm. 

Participants enrolled in the PD Arm will receive the investigational treatment and will also be asked to provide additional blood and tissue samples.

Here is the study overview from the U.S. government's Clinical Trials website:

The study is a non-randomized trial meaning that all patients receive the same treatment.  It is also open-label meaning that clinicians and patients know what Arm of treatment that they are receiving unlike blinded trials where patients do not know their course of treatment.  You'll also note that there is no placebo group.

 

Imperial College in the United Kingdom, home of COVID-19 pandemic modeller Professor Neil Ferguson, author of a flawed report which led directly to the global pandemic lockdown, recently announced the following:

 

In the United Kingdom, the trial is being run in partnership between Imperial College London and Imperial College Healthcare NHS Trust.  The first patient to receive the mRNA-4359 vaccine was injected in late October 2023

In late March 2024, Modern also announced that it was advancing three of its mRNA vaccines to late-stage clinical trials including vaccines for cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV) and Varicella-Zoster virus (VZV) (i.e shingles).  Among the trials for additional mRNA vaccines, we find the following:

  

1.) CMV - CMVictory is a pivotal Phase 3 trial evaluating mRNA-1647 against primary CMV infection in women 16 to 40 years of age. The trial is a randomized, observer-blind, placebo-controlled study designed to evaluate the efficacy, safety and immunogenicity of mRNA-1647. The trial is fully enrolled with approximately 7,300 participants from 290 clinical sites globally.

 

2.) EBV - Moderna's EBV vaccine candidates are designed to tackle multiple EBV-associated conditions, including prevention of IM (mRNA-1189) and MS and post-transplant lymphoproliferative disorder, a subcategory of lymphoma in solid organ transplant patients (mRNA-1195). The Phase 1 trial for mRNA-1189 was designed to test the safety, reactogenicity and immunogenicity of four different dose levels in participants 12 to 30 years of age in the U.S. The randomized, observer-blind, placebo-controlled study showed mRNA-1189 was immunogenic and generally well tolerated across all dose levels. The Company is advancing mRNA-1189 toward a pivotal Phase 3 trial.

The Phase 1 trial for mRNA-1195 was designed to test the safety, reactogenicity and immunogenicity of two drug products at four different dose levels in healthy EBV seropositive participants 18 to 55 years of age in the U.S. The randomized, observer-blind, placebo-controlled study is fully enrolled.

 

3.) HSV - The first in human, fully enrolled Phase 1/2 trial of mRNA-1608 is designed to test safety and immunogenicity and to establish a proof-of-concept of clinical benefit in adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The randomized 1:1:1:1, observer-blind, controlled study is fully enrolled with 300 participants in the U.S.

 

4.) VZV - Moderna's VZV vaccine candidate mRNA-1468 has initial data available from a Phase 1/2 trial, which was designed to test safety and immunogenicity in healthy adults 50 years of age and older in the U.S. The randomized 1:1:1:1:1, observer-blind, active-controlled study of mRNA-1468 elicited strong antigen-specific T cell responses at one month after the second dose and was generally well tolerated. Results of the first interim analysis support the further clinical development of mRNA-1468 for the prevention of shingles. Additional results from the ongoing Phase 1/2 study will be available later this year, including persistence data. The Company is planning for a pivotal Phase 3 trial.

  

Modern is also awaiting regulatory approvals for mRNA-1345, the company's Respiratory Syncytial Virus (RSV) vaccine candidate which is currently undergoing at Phase 2/3 randomized, observer-blind, placebo-controlled, case-driven trial.

 

Looking at human illness through the Moderna lens, one can see that the mRNA vaccine experiment on humanity will continue unabated.  Moderna would have us believe that this newly commerciallized technology is the solution to whatever ails us and seems quite capable of ignoring the long list of potential adverse health effects of this technology that are being observed by clinicians and physicians around the world.  Nonetheless, it's full speed ahead when it comes to mRNA technology.

Moderna's Focus on mRNA Technology

With the exception of politicians, health care officials and the mainstream media who seem to have very little knowledge about the mRNA technology being used in the COVID-19 vaccines, the history of the use of mRNA in vaccines has been fraught with issues.  Nonetheless, Moderna, one of the three main players in the mRNA space is going full bore on the use of this technology for other uses.

  

Here is a brief article that looks at history of the technology as quoted from the Bloomberg School of Public Health at Johns Hopkins University:

 

Here are some quotes:

 

"Messenger RNA, or mRNA, was discovered in the early 1960s; research into how mRNA could be delivered into cells was developed in the 1970s. So, why did it take until the global COVID-19 pandemic of 2020 for the first mRNA vaccine to be brought to market? 

 

The early years of mRNA research were marked by a lot of enthusiasm for the technology but some difficult technical challenges that took a great deal of innovation to overcome. 

 

The biggest challenge was that mRNA would be taken up by the body and quickly degraded before it could “deliver” its message—the RNA transcript—and be read into proteins in the cells. 

 

The solution to this problem came from advances in nanotechnology: the development of fatty droplets (lipid nanoparticles) that wrapped the mRNA like a bubble, which allowed entry into the cells. Once inside the cell, the mRNA message could be translated into proteins, like the spike protein of SARS-CoV-2, and the immune system would then be primed to recognize the foreign protein. 

 

SO, WHAT HAPPENED ONCE THEY FIGURED OUT THIS TECHNOLOGY?

 

The first mRNA vaccines using these fatty envelopes were developed against the deadly Ebola virus, but since that virus is only found in a limited number of African countries, it had no commercial development in the U.S.

 

THEN COVID-19 HIT … WHAT HAPPENED THEN?

 

Remember, the COVID-19 pandemic spurred manufacturers to develop dozens of potential vaccines against SARS-CoV-2 and brought tremendous increases in funding. Some of those vaccines used traditional methods involving adenovirus as the spike protein delivery system—such as the Johnson & Johnson vector vaccine.

 

Thanks to decades of research and innovation, mRNA vaccine technology was ready. With COVID, this technology got its moment and has proven to be extremely safe and effective. Pfizer’s COVID-19 vaccine is the first mRNA product to achieve full FDA approval in the U.S."

 

Proven to be extremely safe and effective?  Hmmm, let's see about that.  Given the widespread government and public health approval of the mRNA technology, it is interesting to note that Moderna's mRNA-1273 vaccine trial isn't scheduled for completion until December 29, 2022 as shown here:

 

 

Nonetheless, Moderna, a company with no product sales revenue until 2020 when its COVID-19 vaccine started rolling out and massive losses attributable to common shareholders as shown here:

 

 

...is going all in for mRNA technology.  

  

Here is a table and a graphic showing Moderna's product pipeline which solely focuses on mRNA:

 

The only product which is currently commercial is its mRNA-1273 COVID-19 vaccine.  While most of its other products are in preclinical or Phase 1 trials including its influenza vaccines, the company's CMV (human cytomegalovirus) vaccine, mRNA-1647, is the second vaccine to undergo Phase 3 trials in the company's history.  With RSV being the new bogeyman in the world of health, it is interesting to note that the company's mRNA-1345 RSV vaccine is currently in Phase 3 trials with completion projected for November 30, 2024 as shown here:

 

 

One has to wonder how long it will be before the FDA approves the mRNA-1345 vaccine given the growing concern about the rapid spread of respiratory Syncytial Virus through the population in recent weeks.

 

I find it fascinating that Moderna is putting all of its "eggs" into the mRNA "basket", particularly given that the trials for its headline product, the mRNA-1273 COVID-19 vaccine, are not yet complete, meaning that it is unclear what potential health issues could be related to the widespread use of this technology over the medium- and long-term.  As well, the fact that Big Pharma is able to conduct its Phase 3 trials at the same time as the vaccines are being administered to the public plays well to shareholders since it helps profitability by reducing the high cost of trials during the development phase of new pharmaceuticals.

Changing the Guidance on the Use of Moderna's mRNA-1273 COVID-19 Vaccine

On September 29, 2021, the Ministry of Health in Ontario, Canada's largest province, released an update to its guidance for the use of COVID-19 vaccines for youth aged 12 to 17 years as shown here:

 

 

Notice this sentence under the "Highlights of changes" because it is of critical importance:

 

"Information regarding a preferential recommendation for Pfizer BioNTech in specific age groups."

  

Here are the key changes:

 

Basically, any young person that is living in the province of Ontario, is between the ages of 12 and 24 and has received the Moderna COVID-19 vaccine for their first dose will now receive the Pfizer-BioNTech COVID-19 for their second and presumably future doses since there is a higher risk of developing myocarditis and pericarditis in that age group, particularly among males.

  

Now, since this pandemic has been all about the "science", let's see what Moderna had to say about the mixing of its mRNA-1273 vaccine with other COVID-19 vaccines in a press release dated September 15, 2021, just two weeks prior to the announced changes to Ontario's vaccine policy:

 

Let's repeat that.  Moderna very, very clearly states that there is no data available on the mixing of its mRNA vaccine with the COVID-19 vaccines created by other companies and that individuals who have received one dose of Moderna's COVID-19 vaccine should receive a second dose of the Moderna vaccine. It is also interesting to note that Moderna admits that additional and potentially serious adverse reactions to its mRNA vaccine may present themselves as the vaccine rollout continues.  In other words, even Moderna is admitting that there are significant unknowns to the mRNA-1273 vaccine, something that you will never hear from government or public health officials who keep insisting that the vaccines are safe and fully tested.

 

So, who do we trust?  A government that has taken the approach that 100 percent of its population should be vaccinated or the vaccine manufacturer?  This is what happens when you roll out and heavily promote a vaccine that is still undergoing Phase 3 trials in the middle of a "pandemic" without fully understanding the repercussions of the vaccines to human health over the short-, medium- and long-term.

Moderna's COVID-19 Vaccine, Breakthrough Infections and Lining Up for a Booster

Just in case you thought that Pfizer's mRNA vaccine was the only one to see waning protection, Moderna has now released the results of a new analysis showing how its iteration of the COVID-19 vaccine stands up over time.

Here is the press release with my highlights:

 

Here are the pertinent highlights with my bolds:

 

Analysis of Open-Label Part of Phase 3 COVE Study (July-August 2021)

 

Today, Moderna is sharing a new analysis of the incidence of breakthrough COVID-19 cases among vaccinated participants in the open-label portion of the Phase 3 COVE study between July 1, 2021 and August 27, 2021. The goal of the analysis is to quantify the impact of waning immunity in the face of the Delta surge in the United States. The analysis compared participants initially randomized to mRNA-1273 (vaccinated from July-October 2020; n=14,746; median follow-up of 13 months since first dose) against participants initially randomized to placebo who were crossed over and vaccinated following Emergency Use Authorization (vaccinated from December 2020-March 2021; n=11,431; median follow-up of 8 months since first dose).

 

In the analysis, 88 breakthrough cases of COVID-19 occurred in the more recently vaccinated group (49.0 cases per 1000 person-years) compared to 162 cases in the group vaccinated last year (77.1 cases per 1000 person-years). The reduction in incidence rates for participants vaccinated more recently compared to participants vaccinated last year was 36% (95% CI: 17-52%). A Cox proportional hazards model showed similar results after adjusting for age and risk factors for severe COVID-19. Fortunately, only 19 severe cases were observed. While not significant, there was a numerical trend towards a lower rate of severe cases in the group vaccinated more recently (3.3 per 1000 person-years) compared to the group vaccinated last year (6.2 per 1000 person-years).

 

And, here's the "money shot" (literally):

 

"The increased risk of breakthrough in this analysis quantifies the impact of waning immunity in the COVE study between the median follow-up time of 8 months and 13 months since first dose. The Company believes this adds to evidence of potential benefit of a booster dose of mRNA-1273. A manuscript has been submitted as a preprint to medRxiv and will be submitted for peer-reviewed publication."

 

This begs the question; how will governments that are insisting upon the issuance of vaccine passports going to handle this?  Are the number of vaccines required to receive a passport going to keep increasing as research shows that the "protection" offered by the mRNA vaccines wanes over time?

 

Of course, Moderna has to "keep up with the Joneses" aka Pfizer in advocating for booster doses.  After all, what a great way to add billions of dollars of profit to the company's bottom line not to mention billions in wealth to the company's insiders!  That way, the mRNA vaccine money printing machine can keep churning out profits for the company's corner office dwellers who have seen Moderna's stock do this over the past five years:

 

 

Moderna shareholders and insiders that invested during the company's lean years (stock was sub $20) have now seen a 2170 percent return on their investment.  Lucky Bill Gates:

Just for fun and in closing, I read through the "Important Safety Information" on Moderna's press release and found these gems, many of which fly in the face of the advice being touted by public health officials and politicians who are pushing a 100 percent vaccinated mantra:

 

1.) Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID-19 Vaccine.

2.) The Moderna COVID-19 Vaccine may not protect all vaccine recipients.

3.) Available data on Moderna COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed infant or on milk production/excretion.

4.) There are no data available on the interchangeability of the Moderna COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.

5.) Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.

Moderna and mRNA Vaccine Research

While Moderna continues the human-wide, government-promoted and mandated Phase 3 trials of its unprecedented mRNA-1273 COVID-19 vaccine, the company appears to be putting significant effort into advancing its mRNA-based vaccine research inventory.  

 

Here is how Moderna defines mRNA (messenger RNA):

 

"Messenger RNA, or mRNA, plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. mRNA provides instructions to cells to make protein. Moderna’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. We are also working to advance the development mRNA therapeutics that restore the activity of missing enzymes responsible for various rare diseases, such as methylmalonic acidemia (MMA) and propionic acidemia (PA)."

  

Messenger RNA vaccines are a completely new line of vaccines.  Here is some background information on mRNA vaccines from Harvard Health Blog

 

"The main goal of a vaccine for a particular infectious agent, such as the virus that causes COVID-19, is to teach the immune system what that virus looks like. Once educated, the immune system will vigorously attack the actual virus, if it ever enters the body.

 

Viruses contain a core of genes made of DNA or RNA wrapped in a coat of proteins. To make the coat of protein, the DNA or RNA genes of the virus make messenger RNA (mRNA); the mRNA then makes the proteins. An mRNA of a specific structure makes a protein of a specific structure.

 

About 30 years ago, a handful of scientists began exploring whether vaccines could be made more simply. What if you knew the exact structure of the mRNA that made the critical piece of a virus’s protein coat, such as the spike protein of the COVID-19 virus?

 

It is relatively easy to make that mRNA in the laboratory, in large amounts. What if you injected that mRNA into someone, and the mRNA then traveled through the bloodstream to be gobbled up by immune system cells, and then those cells started to make the spike protein? Would that educate the immune system?

 

While the concept seems simple, it required decades of work for mRNA vaccines to overcome a series of hurdles. First, scientists learned how to modify mRNA so that it did not produce violent immune system reactions. Second, they learned how to encourage immune system cells to gobble up the mRNA as it passed by in the blood. Third, they learned how to coax those cells to make large amounts of the critical piece of protein. Finally, they learned how to enclose the mRNA inside microscopically small capsules to protect it from being destroyed by chemicals in our blood.

 

Along the way, they also learned that, compared to traditional vaccines, mRNA vaccines can actually generate a stronger type of immunity: they stimulate the immune system to make antibodies and immune system killer cells — a double strike at the virus."

 

Here is a diagram from Moderna showing how its mRNA vaccines work:

 

Here is a video from Moderna featuring the company's president Dr. Stephen Hoge and its Chief Scientific Officer Paolo Martini on how Moderna is delivering on its mRNA therapies:

 

Now, let's look at Moderna's current research on mRNA vaccines, most of which are still in Phase 1 or 2 clinical study with the notable exception of the COVID-19 mRNA-1273 vaccine:  

 

Who is backing this research?  Here's the answer:

 

 

Shocking, isn't it?   In "Gatesworld" there's nothing that can't be solved with a heavy dose of technology and a hefty influx of a seemingly endless bundle of cash.

 

Let's close with this information from the Centers for Disease Control and Prevention on mRNA vaccines:

 

"There are currently no licensed mRNA vaccines in the United States. However, researchers have been studying them for decades.

 

Early stage clinical trials using mRNA vaccines have been carried out for influenza, Zika, rabies, and cytomegalovirus (CMV). Challenges encountered in these early trials included the instability of free RNA in the body, unintended inflammatory outcomes, and modest immune responses. Recent technological advancements in RNA biology and chemistry, as well as delivery systems, have mitigated these challenges and improved their stability, safety, and effectiveness.

 

Beyond vaccines, numerous preclinical and clinical studies have used mRNA to encode cancer antigens to stimulate immune responses targeted at clearing or reducing malignant tumors."

 

Given that mRNA vaccines are unprecedented and that Moderna's mRNA-1273 vaccine is not scheduled to complete its phase 3 clinical trial until October 27, 2022 as shown here:

 

...we are all unwitting animal test subjects in the very early days of a new unproven technology.

 

Moderna, Moncef Slaoui and its Funding Partnerships - America's Tangled Vaccine Web

The hunt for the world's first coronavirus vaccine is taking place with numerous companies and countries seeking to solve the COVID-19 pandemic.  At the forefront, we find one American company that has been given a clear advantage in the process.

On May 15, 2020, Donald Trump announced this:

"Today I want to update you on the next stage of this momentous medical initiative.  It’s called Operation Warp Speed.  That means big and it means fast.  A massive scientific, industrial, and logistical endeavor unlike anything our country has seen since the Manhattan Project.  You really could say that nobody has seen anything like we’re doing, whether it’s ventilators or testing.  Nobody has seen anything like we’re doing now, within our country, since the Second World War.  Incredible.

Its objective is to finish developing and then to manufacture and distribute a proven coronavirus vaccine as fast as possible.  Again, we’d love to see if we could do it prior to the end of the year.  We think we’re going to have some very good results coming out very quickly.  In addition, it will continue accelerating the development of diagnostics and breakthrough therapies….

To date, Operation Warp Speed has brought together all of the experts across the federal government from places like the NIH, CDC, FDA, and many other agencies.  This historic partnership will now bring together the full resources of the Department of Health and Human Services with the Department of Defense.  And we know what that means.  That means the full power and strength of military — the military.  And that — really, talking about the logistics — if we get it, when we get it.  That means the logistics, getting it out, so that everybody can take it.

And today, we’re proud to announce the addition of two of the most highly respected and skilled professionals in our country — worldwide respected.  Operation Warp Speed’s chief scientist will be Dr. Moncef Slaoui, a world-renowned immunologist who helped create 14 new vaccines — that’s a lot of our new vaccines — in 10 years, during his time in the private sector.  One of the most respected men in the world in the production and, really, on the formulation of vaccines." (my bolds)

Notice "...so that EVERYONE can take it".  That sounds pretty non-optional to me.

Until Trump's announcement, Dr. Slaoui was a former member of Moderna, Inc.'s Board of Directors as shown here:

While Moderna may not be a "tip of the tongue" pharmaceutical company, Washington is, in fact, very familiar with the company.  Here is an announcement from Moderna dated April 16, 2020:

Thanks to American taxpayers, the company has benefited from a "donation" of $483 million from the Biomedical Advanced Research and Development Authority or BARDA, part of the Department of Health and Human Services as shown here:

Not only has Moderna benefitted from the generosity of American taxpayers, it has benefitted from none other than the Bill & Melinda Gates Foundation as shown here:

...and here:

As if those connections weren't enough, Dr. Slaoui is also connected to the Gates Foundation through his position on the Board of Directors of the International AIDS Vaccine Initiative (IAVI) as shown here:

..., I bet that you can't guess who funds IAVI?  That's right, the Bill & Melinda Gates Foundation as shown here:

Moderna's timeline of the development of its mRNA-1273 vaccine answer to the COVID-19 pandemic includes this, noting the highlighted portion of the announcement:

While you may not have heard of the Coalition for Epidemic Preparedness Innovations (CEPI), its mission is to "stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.  CEPI also claims the following:

"If a highly contagious and lethal airborne pathogen, with the characteristics of the 1918 Spanish Flu, were to emerge today it is estimated that nearly 33 million people worldwide would die in just 6 months.

The costs of emerging infectious diseases are vast—in both human and economic terms. Recent economic work suggests that the annual global cost of moderately severe to severe pandemics is roughly $570 billion, or 0.7 percent of global income. The cost of a severe pandemic like the 1918 Spanish flu could total as much as 5 percent of global GDP."

Note the use of the "33 million people worldwide would die in just six months" mantra, not entirely dissimilar to the fear being used during the initial days of the pandemic.

By now, you probably have a pretty good idea of who is funding CEPI but here is the list of founding and current donors:

As well, two voting members of CEPI's Scientific Advisory Committee are representatives of the Gates family:

Here's one of the Bill & Melinda Gates Foundation's donations to CEPI:

Let's close this rather complicated posting by looking back at Moderna.  Thus far, Moderna has tested its mRNA-1273 vaccine on 45 individuals between the ages of 18 and 55 with the company claiming success and announcing the start of Phase 2 testing on more human subjects.  It has also announced that it is partnering with Lonza U.S. to produce up to 1 billion doses of its new experimental product mRNA-1273 starting in July 2020:

Unfortunately, by its own admission, Moderna has not successfully created a vaccine for coronaviruses as shown in this quote:

"We had previously collaborated with the NIH on a vaccine for MERS-CoV, which is a different type of coronavirus than the current pandemic. While the program was only at the research stage, it provided significant insights as we launched our efforts for mRNA-1273. Before the Phase 1 study for mRNA-1273, we had not previously tested a coronavirus vaccine in humans."

Caveat emptor.  Moderna is not unique in its inability to create a safe vaccine for coronaviruses; there has never been a vaccine for coronavirus at any time.

The complicated web of one of the world's wealthiest philanthropic armchair virologist, pharmaceutical research and his links to the newly appointed "vaccine czar" Dr. Slaoui should cause us to ponder the rapid "Warp Speed" development of a vaccine dedicated to ending the COVID-19 pandemic.  There are just so many connections between the main players in this drama that conflicts of interest are certain to trump solid science.  With Moderna having a half billion dollars worth of taxpayer funding and the company's solid connections to the Bill Gates "vaccine  funding machine", I suspect that we already have a pretty good idea that the mRNA-1273 vaccine is going to be the vaccine of choice.

Remember this quote about the COVID-19 vaccine from Donald Trump: 

"...so that everyone can take it."